Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease

Title:Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease

Volume: 15 Issue: 5

Author(s): Panagiotis Kitrou, Konstantinos Katsanos, Dimitris Karnabatidis, Lazaros Reppas, Elias Brountzos and Stavros Spiliopoulos*

Affiliation:

• Attiko University Hospital, 2nd Radiology Department, Division of Interventional Radiology, GR 12461, 1st Rimini St, Chaidari, Athens,Greece

Keywords: Peripheral arterial disease, antiplatelet therapy, aspirin, statins, clopidogrel, cilostazol, ticagrelor.

Abstract: Background: Pharmacotherapy is of increasing interest in peripheral arterial disease (PAD), with novel therapies aiming at different factors contributing to the disease. For antiplatelet therapy, there is no unanimous agreement regarding the nature or duration of optimal antiplatelet therapy so as to reduce major adverse cardiovascular and limb-related events (e.g. repeat interventions and amputations). However, evidence on novel more potent antithrombotic agents, drug combinations and personalized antiplatelet therapy for PAD patients is accumulating. Similarly, statins are now considered as a standard of care in PAD patients, due to their multiple actions which include plaque stabilization, antiinflammatory properties and regression of atheroma.

Cite this article as:

Kitrou Panagiotis , Katsanos Konstantinos , Karnabatidis Dimitris , Reppas Lazaros, Brountzos Elias and Spiliopoulos Stavros*, Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease, Current Vascular Pharmacology 2017; 15 (5) . https://dx.doi.org/10.2174/1570161115666170504124911